Sequoia Financial Advisors LLC Sells 16,194 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Sequoia Financial Advisors LLC lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 65,014 shares of the medical equipment provider’s stock after selling 16,194 shares during the period. Sequoia Financial Advisors LLC’s holdings in Zimmer Biomet were worth $5,846,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Key Financial Inc grew its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the period. Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet during the third quarter valued at about $31,000. Flagship Harbor Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at about $32,000. Finally, Grove Bank & Trust raised its holdings in shares of Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $82.24 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The company’s fifty day moving average price is $91.56 and its two-hundred day moving average price is $92.31. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.83 and a 1-year high of $108.29. The company has a market cap of $15.91 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 1.93 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the prior year, the company posted $1.81 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.2%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Wall Street Analyst Weigh In

ZBH has been the topic of several research reports. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. Truist Financial reiterated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. William Blair initiated coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating on the stock. Finally, Wells Fargo & Company dropped their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $102.80.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.